Table 1.
Reference sera used to establish the specificity of COVID-19 IBs
| Source | Characteristic | Number of sera |
|---|---|---|
| IGeneX (human sera) | Leftover, decoded, pre-pandemic sera received for tick-borne diseases testing | 152 |
| CAP and NYSHD Autoimmunity and Allergy (human sera) | Anti-nuclear antibody positive | 5 |
| Anti-dsDNA antibody positive | 2 | |
| Rheumatoid factor positive | 12 | |
| Rheumatoid factor negative | 7 | |
| Elevated IgG | 13 | |
| Elevated IgE | 4 | |
| Normal IgE | 2 | |
| NYB Viral Infections (human sera) | Epstein-Barr virus infection | 7 |
| Herpes simplex virus infection | 4 | |
| Cytomegalovirus infection | 4 | |
| Hepatitis C infection | 5 | |
| HIV infection | 7 | |
| NIH AIDS Reagent Program (human sera) | HIV infection | 3 |
| BEI Resources (human sera) | Respiratory syncytial virus infection | 4 |
| BEI Resources (goat antisera) | Goat antisera to human influenza A virus proteins | 27 |
| Goat antisera to human influenza B virus proteins | 5 |
CAP College of American Pathologists; NYB New York Biologics; NYSH New York State Department of Health; NIH National Institutes of Health; BEI Biodefense and Emerging Infections Research Resources Repository; ds double stranded